WO2002067895A3 - Implant dosage form and use thereof for the delivery of a cholesterol lowering agent - Google Patents

Implant dosage form and use thereof for the delivery of a cholesterol lowering agent Download PDF

Info

Publication number
WO2002067895A3
WO2002067895A3 PCT/US2001/046714 US0146714W WO02067895A3 WO 2002067895 A3 WO2002067895 A3 WO 2002067895A3 US 0146714 W US0146714 W US 0146714W WO 02067895 A3 WO02067895 A3 WO 02067895A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
lowering agent
cholesterol lowering
dosage form
implant dosage
Prior art date
Application number
PCT/US2001/046714
Other languages
French (fr)
Other versions
WO2002067895A2 (en
Inventor
Harry A J Struijker-Boudier
Original Assignee
Durect Corp
Harry A J Struijker-Boudier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp, Harry A J Struijker-Boudier filed Critical Durect Corp
Priority to CA2429898A priority Critical patent/CA2429898C/en
Priority to US10/432,644 priority patent/US20040142902A1/en
Priority to EP01273052A priority patent/EP1335704A2/en
Publication of WO2002067895A2 publication Critical patent/WO2002067895A2/en
Publication of WO2002067895A3 publication Critical patent/WO2002067895A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Implanted, sustained release dosage forms, devices and methods for the delivery of a cholesterol lowering agent.
PCT/US2001/046714 2000-11-16 2001-11-08 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent WO2002067895A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2429898A CA2429898C (en) 2000-11-16 2001-11-08 Devices and methods for cholesterol management
US10/432,644 US20040142902A1 (en) 2001-11-08 2001-11-08 Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
EP01273052A EP1335704A2 (en) 2000-11-16 2001-11-08 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24964400P 2000-11-16 2000-11-16
US60/249,644 2000-11-16

Publications (2)

Publication Number Publication Date
WO2002067895A2 WO2002067895A2 (en) 2002-09-06
WO2002067895A3 true WO2002067895A3 (en) 2003-04-17

Family

ID=22944385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046714 WO2002067895A2 (en) 2000-11-16 2001-11-08 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent

Country Status (3)

Country Link
EP (1) EP1335704A2 (en)
CA (1) CA2429898C (en)
WO (1) WO2002067895A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224903A1 (en) * 2002-12-19 2004-11-11 Stephen Berry Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006521897A (en) 2003-03-31 2006-09-28 アルザ・コーポレーション Osmotic pump with means for dissipating internal pressure
DE602004015755D1 (en) 2003-03-31 2008-09-25 Alza Corp NON-AQUEOUS SINGLE-PHASE VEGETABLE VEHICLES AND FORMULATIONS THAT USE THESE VEHICLES
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
HUE030789T2 (en) * 2007-05-18 2017-06-28 Durect Corp Improved depot formulations
BRPI0811319A2 (en) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc FLUID COMPOSITION, METHOD FOR FORMATION OF A FLUID COMPOSITION, BIODEGRADABLE IMPLANT FORMED IN SITU, METHOD FOR FORMATION OF A BIODEGRADABLE IMPLANT, KIT, IMPLANT AND TREATMENT METHOD
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
SG10201510484YA (en) * 2010-12-20 2016-01-28 Cormatrix Cardiovascular Inc A drug eluting patch for the treatment of localized tissue disease or defect
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
BR112015022023B1 (en) 2013-03-11 2022-12-06 Durect Corporation INJECTABLE CONTROLLED RELEASE COMPOSITION COMPRISING HIGH VISCOSITY LIQUID CARRIER
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (en) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc IMPLANT PLACEMENT AND REMOVAL SYSTEMS
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
KR20220140711A (en) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503520A1 (en) * 1991-03-12 1992-09-16 Glaxo Group Limited Cyclic ketal derivatives
US5837228A (en) * 1990-08-22 1998-11-17 Merck & Co., Inc. Bioerodible implants
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837228A (en) * 1990-08-22 1998-11-17 Merck & Co., Inc. Bioerodible implants
EP0503520A1 (en) * 1991-03-12 1992-09-16 Glaxo Group Limited Cyclic ketal derivatives
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE SCISEARCH [online] BUCHWALD H (REPRINT): "CHOLESTEROL INHIBITION, CANCER, AND CHEMOTHERAPY", XP002221937, retrieved from STN Database accession no. 292994 *
DATABASE SCISEARCH [online] JOLES J (REPRINT) ET AL: "SUBCUTANEOUS ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS IN HYPERLIPEMIC AND NORMAL RATS", XP002221936, retrieved from STN Database accession no. 610133 *
LABORATORY ANIMALS, (OCT 1992) VOL. 26, NO. 4, PP. 269-280. ISSN: 0023-6772., UNIV UTRECHT, FAC MED, DEPT NEPHROL, UTRECHT, NETHERLANDS;UNIV UTRECHT, FAC MED, DEPT INTERNAL MED, UTRECHT, NETHERLANDS; UNIV UTRECHT, FAC MED, DEPT PHARMACEUT, UTRECHT, NETHERLANDS; ERASMUS UNIV, DE *
LANCET, (09 MAY 1992) VOL. 339, NO. 8802, PP. 1154-1156. ISSN: 0140-6736., UNIV MINNESOTA, DEPT SURG, BOX 290 UMHC, 420 DELAWARE ST SE, MINNEAPOLIS, MN, 55455 (Reprint) *
See also references of EP1335704A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
CA2429898A1 (en) 2002-09-06
EP1335704A2 (en) 2003-08-20
CA2429898C (en) 2011-02-22
WO2002067895A2 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
WO2002067895A3 (en) Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
AU2001281277A1 (en) Methods and devices for delivering a ventricular stent
AU2003276098A1 (en) Expandable medical implant and percutaneous delivery
AU5367501A (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
WO2005027794A3 (en) Medical devices
WO2003028660A3 (en) Drug delivery devices and methods
AU2001273341A1 (en) An implantable or insertable therapeutic agent delivery device
AU8127701A (en) Methods and devices for delivering a ventricular stent
MXPA03007590A (en) Compositions and methods for enhancing drug delivery across and into ocular tissues.
AU2002240275A1 (en) Methods and devices for delivering occlusion elements
AU2001296217A1 (en) Magnetically navigated pacing leads, and methods for delivering medical devices
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
EP1143935A3 (en) Controlled-release biocompatible ocular drug delivery implant devices and methods
AU2001238386A1 (en) Medication delivery devices
AU1453602A (en) Systems, devices and methods for suturing patient tissue
AU2001254786A1 (en) Medical implant
AU2001295850A1 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2003226770A1 (en) Intravaginal reservoir drug delivery devices
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
AU2001295979A1 (en) Medicinal compositions, dose and method for treating malaria
HK1041227A1 (en) Sustained release implant and methods for preparation thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2429898

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001273052

Country of ref document: EP

Ref document number: 2002258361

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001273052

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10432644

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP